Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Files NDA for Intestinal Amebiasis Treatment Paromomycin in Japan
December 26, 2011
- Novo Nordisk Pharma Submits NDA for Insulin Degludec
December 26, 2011
- Takeda to Set Up New Unit to Support Investigator-Initiated Research
December 22, 2011
- BMKK, Pfizer Japan Apply for Apixaban for SPAF in Japan
December 22, 2011
- Takeda to Acquire Intellikine to Enhance Oncology Pipeline
December 22, 2011
- Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo
December 22, 2011
- Daiichi Sankyo Grants Marketing Rights for Cravit to Ranbaxy in Malaysia
December 22, 2011
- Rohto’s Mentholatum Medi-Quick H on Track to Become Hit Product in 1st Year
December 22, 2011
- Nexium Takes No. 1 and No. 2 Position in HP Market: RepTrack Survey
December 21, 2011
- MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya
December 21, 2011
- Chugai to Establish Pool System of Candidate Leaders
December 20, 2011
- Meiji Seika Pharma Licenses Udenafil from Dong-A Pharmaceutical
December 20, 2011
- GSK Applies for Add’l Indication for Botox for Axillary Hyperhidrosis
December 20, 2011
- SMBC Nikko Securities Includes Astellas Pharma in 20 Stocks to Watch in 2012
December 19, 2011
- Takeda Decides not to Commercialize Peginesatide in Japan
December 19, 2011
- Valeant Announces Successful Results from PIII Onychomycosis Study of Efinaconazole
December 19, 2011
- Pfizer Tops Doctor Survey Rankings for Pharmaceutical Company Website Access
December 16, 2011
- Chugai to Set Up Company in Singapore Targeting Antibody Drug Discovery
December 16, 2011
- Sanofi-aventis Appeals to IP High Court Claiming Allegra’s Use Patents
December 16, 2011
- Eisai Receives Approval for Halaven in Canada
December 16, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…